Standout Papers

Lecanemab in Early Alz... 2009 2026 2014 2020 2.4k
  1. Lecanemab in Early Alzheimer’s Disease (2022)
    Christopher H. van Dyck, Chad J. Swanson et al. New England Journal of Medicine
  2. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease (2010)
    Kwasi G. Mawuenyega, Wendy Sigurdson et al. Science
  3. Alzheimer's disease (2015)
    Colin L. Masters, Randall J. Bateman et al. Nature Reviews Disease Primers
  4. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle (2009)
    Miranda M. Lim, Randall J. Bateman et al. Science
  5. Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance (2011)
    Joseph M. Castellano, Jungsu Kim et al. Science Translational Medicine
  6. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019)
    Suzanne E. Schindler, James G. Bollinger et al. Neurology
  7. Tau Kinetics in Neurons and the Human Central Nervous System (2018)
    Chihiro Sato, Nicolas R. Barthélemy et al. Neuron
  8. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis (2017)
    Vitaliy Ovod, Kwasi G. Mawuenyega et al. Alzheimer s & Dementia
  9. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease (2020)
    Nicolas R. Barthélemy, Kanta Horie et al. The Journal of Experimental Medicine
  10. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease (2021)
    Shorena Janelidze, Charlotte E. Teunissen et al. JAMA Neurology
  11. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease (2022)
    Shorena Janelidze, Divya Bali et al. Brain
  12. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study (2022)
    Eric McDade, Jeffrey L. Cummings et al. Alzheimer s Research & Therapy
  13. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis (2021)
    Tim West, Kristopher M. Kirmess et al. Molecular Neurodegeneration
  14. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance (2022)
    Alexa Pichet Binette, Shorena Janelidze et al. Alzheimer s & Dementia
  15. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios (2023)
    Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology
  16. Disease staging of Alzheimer’s disease using a CSF-based biomarker model (2024)
    Gemma Salvadó, Kanta Horie et al. Nature Aging
  17. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease (2025)
    Kanta Horie, Gemma Salvadó et al. Nature Medicine

Immediate Impact

15 by Nobel laureates 47 from Science/Nature 255 standout
Sub-graph 1 of 13

Citing Papers

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
2024 Standout
98 intermediate papers

Works of Randall J. Bateman being referenced

Lecanemab in Early Alzheimer’s Disease
2022 Standout
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
2019
and 38 more

Author Peers

Author Last Decade Papers Cites
Randall J. Bateman 11634 5337 4703 245 18.6k
Gary W. Small 9888 7069 4166 241 20.3k
Simon Lovestone 9287 5157 7580 363 20.4k
Lennart Minthon 10938 8176 4128 263 18.5k
Elaine R. Peskind 7742 5502 4731 293 22.4k
Leon J. Thal 8601 8706 4203 203 24.8k
Anne M. Fagan 14760 9167 6030 286 25.4k
John H. Growdon 12009 6067 4957 235 23.6k
Patrizia Mecocci 7505 4001 5651 322 19.2k
Jin‐Tai Yu 8634 4487 6950 448 22.8k
Lan Tan 9032 4869 6399 554 23.1k

All Works

Loading papers...

Rankless by CCL
2026